WO2016135171A1 - Pharmaceutical combinations of dronedarone and dabigatran - Google Patents

Pharmaceutical combinations of dronedarone and dabigatran Download PDF

Info

Publication number
WO2016135171A1
WO2016135171A1 PCT/EP2016/053819 EP2016053819W WO2016135171A1 WO 2016135171 A1 WO2016135171 A1 WO 2016135171A1 EP 2016053819 W EP2016053819 W EP 2016053819W WO 2016135171 A1 WO2016135171 A1 WO 2016135171A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical combination
pellets
combination according
dronedarone
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/053819
Other languages
French (fr)
Inventor
Ali TÜRKYILMAZ
Gülay Yelken
Sevgi Gökcek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2016135171A1 publication Critical patent/WO2016135171A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt in combination with comprising dabigatran or a pharmaceutically acceptable salt or polymorph thereof and at least one pharmaceutically acceptable excipient.
  • Dronedarone is a noniodinated benzofuran derivative with antiarrhythmic properties. It is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane sulfonyl group was added. These modifications reduce thyroid and other adverse effects and makes dronedarone less lipophilic, with a shorter half-life.
  • the chemical name of dronedarone is N-[2-butyl-3-[4-[3- (dibutylamino)propoxy]benzoyl]-1 -benzofuran-5-yl]methanesulfonamide and it has the structure shown in the following formula I .
  • Dronedarone hydrochloride (shown in formula II) is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. Following oral administration in fed conditions, it is well absorbed from intestines to blood. It was approved by the FDA on 2009 and marketed under the brandname MULTAQTM. Recommended dose is one tablet of 400 mg twice a day with morning and evening meals. In prior art, dronedarone and pharmaceutically acceptable salts thereof are described in EP 0 471 609 B1 . US 7 323 493 B1 discloses tablet formulations of dronedarone HCI.
  • DTIs Direct Thrombin Inhibitors
  • IV bivalirudin
  • IV lepirudin
  • desirudin argatroban
  • dabigatran dabigatran etexilate
  • melagatran melagatran
  • ximelagatran oral formulation but liver complications
  • Dabigatran etexilate (Formula III), which is already known from WO 98/37075, is a competitive reversible non-peptide antagonist of thrombin. It is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-vascular atrial fibrilation.
  • Thrombin is a multifunctional enzyme which converts fibrinogen to fibrin, cross-linking fibrin monomers via activation of factor XIII and augmenting further thrombin production via the activation of factors V and VIII. It also activates platelets, generates anticoagulant activity via activation of protein C and initiates numerous cellular processes.
  • the methane sulphonic acid addition salt of dabigatran etexilate which is commercially available under the trade name PRADAXA® (in the strength of 75, 1 10, 150mg)
  • pellet composition of dabigatran etexilate mesylate (DEM) (Formula IV) is also disclosed in EP1870100.
  • This composition is formulated with a core material consisting of organic acid and an active layer which covers the core.
  • dronedarone as an antiarithmic and dabigatran as an anticoagulant are combined in one dosage form and an effective and safe treatment of cardiovascular diseases is achieved.
  • the present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt thereof in combination with dabigatran or a pharmaceutically acceptable salt or polymorph thereof and at least one pharmaceutically acceptable excipient.
  • dronedarone or a pharmaceutically acceptable salt used in this present invention is dronedarone hydrochloride.
  • dronedarone hydrochloride is present in an amount of between 5.0 to 98.0 %, preferably between 20.0 to 98.0 % and more preferably it is 50.0 to 95.0 % by weight of total formulation.
  • dronedarone hydrochloride present in an amount of between 50 to 1000 mg, preferably 200 to 800 mg and more preferably it is 400 to 800 mg.
  • dabigatran or a pharmaceutically acceptable salt or polymorph is the etexilate or etexilate mesylate salt of dabigatran.
  • dabigatran or a pharmaceutically acceptable salt is dabigatran etexilate mesylate.
  • dabigatran etexilate mesylate is present in an amount of between 1 .0 to 85.0 %, preferably between 1 .0 to 60.0 % and more preferably it is 5.0 to 50.0 % by weight of total formulation.
  • dabigatran etexilate mesylate is present in an amount of between 30 to 350 mg, preferably 50 to 300 mg and more preferably it is 50 to 250 mg.
  • dronedarone HCI is used as an antiarrithmic in combination with dabigatran etexilate mesylate as an anticoagulant, for use in the treatment of cardiac arrhythmia and blood clotting and to prevent serious or life-threatening side effects in patients.
  • a pharmaceutical dosage form comprising dronedarone HCI in combination with dabigatran etexilate mesylate has been developed providing a stable pharmaceutical combination with safe and effective dissolution profiles for each drug molecule.
  • the ratios used in this present invention ensure the required effective doses for the treatment and provide stability for both dronedarone HCI and dabigatran etexilate mesylate.
  • pharmaceutical combination formulated in one dosage form provides desired dissolution profile for both dronedarone HCI and dabigatran etexilate mesylate.
  • the pharmaceutical combination is in the form of solid, liquid or semisolid dosage form.
  • these pharmaceutical combinations are administrated oral, parenteral, intranasal, sublingual, transdermal, transmucosal, ophthalmic, intravenous, pulmonary, intramuscular or rectal administration, and preferably for oral administration.
  • the pharmaceutical combination is in the form of tablets, coated or uncoated tablets, capsules, multilayer tablets, buccal tablets, sublingual tablets, tablet in tablets, in-lay tablets, effervescent combinations, effervescent tablets, immediate release tablets, modified release tablets, ODT (orally disintegrating tablet), film-coated tablets, orally disintegrating tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, powders, mini tablets, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, sterile solutions or suspensions, sterile ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, sachets; films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions, emulsions and thereof.
  • said pharmaceutical combination is formulated in the form of tablet or capsule or multilayer tablet comprising dronedarone HCI pellets and dabigatran etexilate mesylate pellets.
  • Dronedarone is a drug molecule which is well absorbed in intestine and dabigatran is a drug molecule which is well absorbed in stomach.
  • it is provided to dissolve the dronedarone HCI pellets in intestine not in stomach and dabigatran etexilate mesylate pellets in stomach.
  • said pharmaceutical combination dronedarone HCI pellets comprises an enteric coating.
  • enteric coating used in this present invention ensures absorption of dronedarone HCI not in stomach but in intestine.
  • the present invention provides a pharmaceutical combination comprises an enteric coating which covers dronedarone HCI layer and which separates dabigatran etexilate mesylate and dronedarone HCI layers.
  • Enteric coating ensures the stability of dronedarone HCI in stomach and by the virtue of the enteric coating, interaction between the dabigatran etexilate mesylate and dronedarone HCI molecules is also prevented at the same time.
  • Another important reason is that the formulations of the drug molecules with different release properties can be provided in the same dosage form with the enteric coating.
  • dabigatran etexilate mesylate and dronedarone HCI molecules are formulated in a way not to interact, and at the same time it is provided that these molecules remain stable in their own form.
  • desired release profiles are achieved for each drug molecules for a safe and effective treatment of cardiovascular diseases.
  • dronedarone HCI pellets comprises an enteric coating is selected from the group comprising cellulose acetate phthalate, methacrylic acid copolymers (Eudragit L types (methacrylic acid, ethyl acrylate copolymers), Eudragit RL and RS types (copolymer of ethyl acrylate, methyl methacrylate and ammonia methacrylate), Eudragit-S types (Methacrylic acid, methyl methacrylate copolymer)), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and methacrylic acid copolymer type C.
  • methacrylic acid copolymers Eudragit L types (methacrylic acid, ethyl acrylate copolymers), Eudragit RL and RS types (copolymer of ethyl acrylate, methyl methacrylate and ammonia methacryl
  • said pharmaceutical combination is in the form of tablet or capsule or multilayer tablet comprising dabigatran etexilate mesylate pellets and dronedarone HCI pellets which are in the form of separated pellets or bilayer or multilayer pellets.
  • said dronedarone HCI pellets comprises mannitol or pregelatinized starch or carbomer or croscarmellose sodium or polyvinylpyrrolidone (PVP) or polyvinyl alcohol or sugar pellet or microcrystalline cellulose (MCC) pellet or hydroxypropyl cellulose or coloring agent or mixtures thereof as pharmaceutically acceptable excipients.
  • said dabigatran etexilate mesylate pellets comprises polyvinyl alcohol (PVA) or isopropyl alcohol (I PA) or sodium alginate or methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or propylene glycol or lactose monohydrate or mannitol or sugar pellet or polyvinylpyrrolidone (PVP) or mixtures thereof as pharmaceutically acceptable excipients.
  • PVA polyvinyl alcohol
  • I PA isopropyl alcohol
  • I PA sodium alginate or methacrylic acid-ethyl acrylate copolymer
  • PVP polyvinylpyrrolidone
  • At least one pharmaceutically acceptable excipient is selected from the group comprising buffering agents, stabilizers, binders, diluents, dispersing agents, lubricants, glidants, disintegrants, plasticizers, preservatives, sweeteners, flavoring agents, coloring agents or mixtures thereof.
  • Suitable buffering agents may comprise but not limited to alkali metal citrate, citric acid/sodium citrate, tartaric acid, fumaric acid, sorbic acid, citric acid, succinic acid, adipic acid, ascorbic acid, sorbic acid, glutaric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium hydrogen phthalate, sodium hydrogen phthalate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, hydrochloric acid/sodium hydroxide or mixtures thereof, and preferably citric acid, fumaric acid, ascorbic acid, sodium dihydrogen phosphate or mixtures thereof.
  • Suitable stabilizers may comprise but not limited to citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid, gallic acid esters or the mixtures thereof, and preferably, citric acid, fumaric acid, arginine or mixtures thereof.
  • Suitable binders may include but not limited to xanthan gum, pregelatinized starch, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, alginic acid, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • Suitable diluents may comprise but not limited to mannitol, lactose, microcrystalline cellulose, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable dispersing agents may comprise but not limited to calcium silicate, magnesium aluminum silicate or mixtures thereof.
  • Suitable lubricants may comprise but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • Suitable glidants may comprise but not limited to talc, aluminium silicate, colloidal silica, starch or mixtures thereof.
  • Suitable disintegrants may comprise but not limited to pregelatinized starch, cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • Suitable plasticizers may comprise but not limited to polyethylene glycols of different molecular weights, propylene glycol, glycerine, triethyl citrate (TEC), triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributhyl citrate (TBC), castor oil, dibutyl sebacate (DBS), diacetylated monogglycerides or mixtures thereof.
  • TEC triethyl citrate
  • DEP diethyl phthalate
  • DBP dibutyl phthalate
  • THC tributhyl citrate
  • DBS dibutyl sebacate
  • Suitable preservatives may comprise but not limited to methyl paraben, propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene, boric acid, sorbic acid, benzyl alcohol, benzalconium chloride, parahydroxybenzoic acids or butylated hydroxyanisole and the like or mixtures thereof.
  • Suitable sweeteners may comprise but not limited to aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose or sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
  • Suitable flavoring agents may comprise but not limited to menthol, peppermint, cinnamon, chocolate, vanillin or fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries or mixtures thereof.
  • Suitable coloring agents may comprise but not limited to ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • D&C Drug & Cosmetic
  • Dronedarone HCI pellets Dronedarone HCI, mannitol and pregelatinized starch are mixed together then by spraying polyvinyl pyrrolidone solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding cellulose acetate phthalate as enteric coating and the dronedarone HCI are coated by spraying this mixture.
  • Dabigatran Adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum are mixed together.
  • Alcoholic polyvinyl alcohol (PVA) or I PA (isopropyl alcohol) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique.
  • the pellets are coated with sodium alginate in fluidized bed so acid pellets are manufactured.
  • DEM diabigatran etaxylate mesylate
  • Eudragit EPO alcoholic methacrylic acid-ethyl acrylate copolymer
  • PVA polyvinyl alcohol
  • the DEM and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules.
  • Dronedarone HCI pellets Dronedarone HCI, mannitol and pregelatinized starch are mixed together then by spraying carbomer solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding copolymer of ethyl acrylate, methyl methacrylate and ammonia methacrylate as enteric coating and the dronedarone HCI pellets are coated by spraying this mixture in fluidized bed.
  • Dabigatran pellets DEM and mannitol are mixed together.
  • Alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique.
  • the solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum.
  • This solution is sprayed onto the DEM pellets by fluidized bed pelletizing technique so multilayer pellets are manufactured.
  • the DEM and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules.
  • PVP polyvinylpyrrolidone
  • microcrystalline cellulose or 5.0 - 40.00
  • Dronedarone HCI pellets Dronedarone HCI, mannitol and croscarmellose sodium are mixed together then by spraying carbomer solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding methacrylic acid, methyl methacrylate copolymer as enteric coating and the dronedarone HCI pellets which were coated with the enteric coating by spraying this mixture.
  • Alcoholic solution/dispersion is prepared by adding DEM and PVP.
  • Sugar pellets are coated with this solution/dispersion.
  • the sugar pellets which were coated with the active ingredient are coated with methacrylic acid-ethyl acrylate copolymer (Eudragit EPO or Polyvinyl alcohol (PVA) and then with PVP solution so DEM pellets are manufactured.
  • Production Process of inorganic acid pellets Microcrystalline cellulose or mannitol or lactose and silicon dioxide are blended, then by spraying dilute nitric acid soution a wet mass is formed by high shear granulator or fluid bed granulator. The pellets are coated by methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution in fluidized bed so inorganic acid pellets are manufactured.
  • Dronedarone pellets and Dabigatran etexilate mesylate pellets and inorganic acid pellets are mixed.
  • the pellets are first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules.
  • Example 4
  • a solution/dispersion is prepared by adding dronedarone and PVP.
  • Sugar pellets are coated with this solution/dispersion.
  • the sugar pellets which were coated with the dronedarone HCI are coated with polyvinyl acetate phthalate so dronedarone HCI pellets are manufactured.
  • DEM and mannitol are mixed with alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution.
  • EOM and mannitol are mixed with alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution.
  • This mixture is sprayed onto dronedarone HCI pellets.
  • the solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid) and xanthan gum. This solution is sprayed onto the pellets so multilayer pellets are manufactured.
  • the multilayer pellets
  • Dronedarone HCI pellets A solution/dispersion is prepared by adding Dronedarone HCI and PVP. Sugar pellets are coated with this solution/dispersion. The sugar pellets which were coated with the active ingredient are coated with methacrylic acid co-polymer type C so Dronedarone HCI pellets are manufactured.
  • Dabigatran pellets are coated with organic acid: DEM and mannitol monohydrate are mixed together.
  • Alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique.
  • the solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum. This solution is sprayed onto the DEM pellets by fluidized bed pelletizing technique so multilayer pellets are manufactured.
  • Dabigatran etexilate mesylate and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed by multilayer rotary tablet press machine or dry tablet in tablet or inlay tablets which have dronedarone HCI pellets on the core are produced with special tablet press machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt thereof in combination with dabigatran or a pharmaceutically acceptable salt or polymorph and at least one pharmaceutically acceptable excipient.

Description

PHARMACEUTICAL COMBINATIONS OF DRONEDARONE AND DABIGATRAN
Field of Invention
The present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt in combination with comprising dabigatran or a pharmaceutically acceptable salt or polymorph thereof and at least one pharmaceutically acceptable excipient.
The background of the invention
Dronedarone is a noniodinated benzofuran derivative with antiarrhythmic properties. It is an amiodarone analog that differs structurally from amiodarone in that the iodine moiety was removed and a methane sulfonyl group was added. These modifications reduce thyroid and other adverse effects and makes dronedarone less lipophilic, with a shorter half-life. The chemical name of dronedarone is N-[2-butyl-3-[4-[3- (dibutylamino)propoxy]benzoyl]-1 -benzofuran-5-yl]methanesulfonamide and it has the structure shown in the following formula I .
Figure imgf000002_0001
Formula I: Dronedarone Formula II: Dronedarone hydrochloride
Dronedarone hydrochloride (shown in formula II) is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. Following oral administration in fed conditions, it is well absorbed from intestines to blood. It was approved by the FDA on 2009 and marketed under the brandname MULTAQ™. Recommended dose is one tablet of 400 mg twice a day with morning and evening meals. In prior art, dronedarone and pharmaceutically acceptable salts thereof are described in EP 0 471 609 B1 . US 7 323 493 B1 discloses tablet formulations of dronedarone HCI. Presently there are numerous antithrombotic drugs which are widely available, they also called as Direct Thrombin Inhibitors (DTIs) which are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin. DTIs comprise hirudin, bivalirudin (IV), lepirudin, desirudin, argatroban (IV), dabigatran, dabigatran etexilate (oral formulation), melagatran, ximelagatran (oral formulation but liver complications) and pro-drugs thereof.
Dabigatran etexilate (Formula III), which is already known from WO 98/37075, is a competitive reversible non-peptide antagonist of thrombin. It is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-vascular atrial fibrilation. Thrombin is a multifunctional enzyme which converts fibrinogen to fibrin, cross-linking fibrin monomers via activation of factor XIII and augmenting further thrombin production via the activation of factors V and VIII. It also activates platelets, generates anticoagulant activity via activation of protein C and initiates numerous cellular processes.
Figure imgf000003_0001
Formula III: Dabigatran etexilate
The methane sulphonic acid addition salt of dabigatran etexilate, which is commercially available under the trade name PRADAXA® (in the strength of 75, 1 10, 150mg), pellet composition of dabigatran etexilate mesylate (DEM) (Formula IV) is also disclosed in EP1870100. This composition is formulated with a core material consisting of organic acid and an active layer which covers the core.
Figure imgf000004_0001
Formula IV: Dabigatran etexilate mesylate
Based on common general knowledge in the art, in the treatment of cardiac arrhythmia especially atrial fibrillation, antiarrhythmic drugs are commonly used in combination with anticoagulants. However, in prior art, there is no formulation which combines dronedarone and dabigatran in one dosage form. Instead of one per se use, combining more than one molecule in one dosage form increases the patients' quality of life and patients' compliance. Therefore, a combination of dronedarone and dabigatran etexilate as an anticoagulant in a suitable pharmaceutical dosage formulation is needed in the art.
On the other side, there are many challenges while combining two or more molecules in a dosage form such as dissolution, compatibility and stability problems. Each drug molecule has different chemical properties and dissolution properties. They may follow different absorption and distribution pathways after administration. For that reason, it is not easy to combine drug molecules in a same dosage form with desired dissolution profiles. They also may react with each other or with other used excipients and that may cause undesired instability problems. Moreover, it is well known that even drugs used in the same therapeutic area or even for treating the same indication cannot always be combined into safe and efficacious dosage forms with the expectation of at least additive therapeutic effects.
In this present invention, dronedarone as an antiarithmic and dabigatran as an anticoagulant are combined in one dosage form and an effective and safe treatment of cardiovascular diseases is achieved.
Detailed Description Of The Invention The present invention relates to a pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt thereof in combination with dabigatran or a pharmaceutically acceptable salt or polymorph thereof and at least one pharmaceutically acceptable excipient.
According to one embodiment, dronedarone or a pharmaceutically acceptable salt used in this present invention is dronedarone hydrochloride.
According to one embodiment, dronedarone hydrochloride (HCI) is present in an amount of between 5.0 to 98.0 %, preferably between 20.0 to 98.0 % and more preferably it is 50.0 to 95.0 % by weight of total formulation.
According to this embodiment, dronedarone hydrochloride present in an amount of between 50 to 1000 mg, preferably 200 to 800 mg and more preferably it is 400 to 800 mg.
According to one embodiment, dabigatran or a pharmaceutically acceptable salt or polymorph is the etexilate or etexilate mesylate salt of dabigatran. According to one embodiment, dabigatran or a pharmaceutically acceptable salt is dabigatran etexilate mesylate.
According to one embodiment, dabigatran etexilate mesylate is present in an amount of between 1 .0 to 85.0 %, preferably between 1 .0 to 60.0 % and more preferably it is 5.0 to 50.0 % by weight of total formulation.
According to this embodiment, dabigatran etexilate mesylate is present in an amount of between 30 to 350 mg, preferably 50 to 300 mg and more preferably it is 50 to 250 mg. In this present invention, dronedarone HCI is used as an antiarrithmic in combination with dabigatran etexilate mesylate as an anticoagulant, for use in the treatment of cardiac arrhythmia and blood clotting and to prevent serious or life-threatening side effects in patients. In one embodiment, a pharmaceutical dosage form comprising dronedarone HCI in combination with dabigatran etexilate mesylate has been developed providing a stable pharmaceutical combination with safe and effective dissolution profiles for each drug molecule.
According to one embodiment, the ratios used in this present invention ensure the required effective doses for the treatment and provide stability for both dronedarone HCI and dabigatran etexilate mesylate.
In this embodiment, it has been found that in spesific ratio of dronedarone HCI to dabigatran etexilate mesylate which is between 0.10 - 50.0(w/w), preferably 1 .0 - 35.0 (w/w) and more preferably 1 .0 - 30.0 (w/w) helps the formulation easily processed into a dosage form, in desired weight which can easily be swallowed by the patients, while maintaining stability of the combination.
In one embodiment, in this present invention, pharmaceutical combination formulated in one dosage form provides desired dissolution profile for both dronedarone HCI and dabigatran etexilate mesylate.
According to one embodiment of this invention, the pharmaceutical combination is in the form of solid, liquid or semisolid dosage form.
In this embodiment, these pharmaceutical combinations are administrated oral, parenteral, intranasal, sublingual, transdermal, transmucosal, ophthalmic, intravenous, pulmonary, intramuscular or rectal administration, and preferably for oral administration. According to one embodiment, the pharmaceutical combination is in the form of tablets, coated or uncoated tablets, capsules, multilayer tablets, buccal tablets, sublingual tablets, tablet in tablets, in-lay tablets, effervescent combinations, effervescent tablets, immediate release tablets, modified release tablets, ODT (orally disintegrating tablet), film-coated tablets, orally disintegrating tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, powders, mini tablets, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, sterile solutions or suspensions, sterile ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, sachets; films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions, emulsions and thereof. In one embodiment said pharmaceutical combination is formulated in the form of tablet or capsule or multilayer tablet.
In one embodiment said pharmaceutical combination is formulated in the form of tablet or capsule or multilayer tablet comprising dronedarone HCI pellets and dabigatran etexilate mesylate pellets.
Dronedarone is a drug molecule which is well absorbed in intestine and dabigatran is a drug molecule which is well absorbed in stomach. In this combination of this present invention, it is provided to dissolve the dronedarone HCI pellets in intestine not in stomach and dabigatran etexilate mesylate pellets in stomach.
In one embodiment, said pharmaceutical combination dronedarone HCI pellets comprises an enteric coating.
According to one embodiment, enteric coating used in this present invention ensures absorption of dronedarone HCI not in stomach but in intestine.
The present invention provides a pharmaceutical combination comprises an enteric coating which covers dronedarone HCI layer and which separates dabigatran etexilate mesylate and dronedarone HCI layers. Enteric coating ensures the stability of dronedarone HCI in stomach and by the virtue of the enteric coating, interaction between the dabigatran etexilate mesylate and dronedarone HCI molecules is also prevented at the same time. Another important reason is that the formulations of the drug molecules with different release properties can be provided in the same dosage form with the enteric coating. Thus, dabigatran etexilate mesylate and dronedarone HCI molecules are formulated in a way not to interact, and at the same time it is provided that these molecules remain stable in their own form. Moreover, desired release profiles are achieved for each drug molecules for a safe and effective treatment of cardiovascular diseases.
In this embodiment of this present invention, dronedarone HCI pellets comprises an enteric coating is selected from the group comprising cellulose acetate phthalate, methacrylic acid copolymers (Eudragit L types (methacrylic acid, ethyl acrylate copolymers), Eudragit RL and RS types (copolymer of ethyl acrylate, methyl methacrylate and ammonia methacrylate), Eudragit-S types (Methacrylic acid, methyl methacrylate copolymer)), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and methacrylic acid copolymer type C. In this embodiment of the present invention, said pharmaceutical combination is in the form of tablet or capsule or multilayer tablet comprising dabigatran etexilate mesylate pellets and dronedarone HCI pellets which are in the form of separated pellets or bilayer or multilayer pellets. In an embodiment of the present invention said dronedarone HCI pellets comprises mannitol or pregelatinized starch or carbomer or croscarmellose sodium or polyvinylpyrrolidone (PVP) or polyvinyl alcohol or sugar pellet or microcrystalline cellulose (MCC) pellet or hydroxypropyl cellulose or coloring agent or mixtures thereof as pharmaceutically acceptable excipients.
In this embodiment of the present invention said dabigatran etexilate mesylate pellets comprises polyvinyl alcohol (PVA) or isopropyl alcohol (I PA) or sodium alginate or methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or propylene glycol or lactose monohydrate or mannitol or sugar pellet or polyvinylpyrrolidone (PVP) or mixtures thereof as pharmaceutically acceptable excipients.
According to the challenges mentioned above the selection of the excipients thus essential. According to this embodiment, at least one pharmaceutically acceptable excipient is selected from the group comprising buffering agents, stabilizers, binders, diluents, dispersing agents, lubricants, glidants, disintegrants, plasticizers, preservatives, sweeteners, flavoring agents, coloring agents or mixtures thereof.
Suitable buffering agents may comprise but not limited to alkali metal citrate, citric acid/sodium citrate, tartaric acid, fumaric acid, sorbic acid, citric acid, succinic acid, adipic acid, ascorbic acid, sorbic acid, glutaric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium hydrogen phthalate, sodium hydrogen phthalate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, hydrochloric acid/sodium hydroxide or mixtures thereof, and preferably citric acid, fumaric acid, ascorbic acid, sodium dihydrogen phosphate or mixtures thereof. Suitable stabilizers may comprise but not limited to citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid, gallic acid esters or the mixtures thereof, and preferably, citric acid, fumaric acid, arginine or mixtures thereof.
Suitable binders may include but not limited to xanthan gum, pregelatinized starch, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, alginic acid, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
Suitable diluents may comprise but not limited to mannitol, lactose, microcrystalline cellulose, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
Suitable dispersing agents may comprise but not limited to calcium silicate, magnesium aluminum silicate or mixtures thereof.
Suitable lubricants may comprise but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
Suitable glidants may comprise but not limited to talc, aluminium silicate, colloidal silica, starch or mixtures thereof. Suitable disintegrants may comprise but not limited to pregelatinized starch, cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof. Suitable plasticizers may comprise but not limited to polyethylene glycols of different molecular weights, propylene glycol, glycerine, triethyl citrate (TEC), triacetin, diethyl phthalate (DEP), dibutyl phthalate (DBP), tributhyl citrate (TBC), castor oil, dibutyl sebacate (DBS), diacetylated monogglycerides or mixtures thereof. Suitable preservatives may comprise but not limited to methyl paraben, propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene, boric acid, sorbic acid, benzyl alcohol, benzalconium chloride, parahydroxybenzoic acids or butylated hydroxyanisole and the like or mixtures thereof. Suitable sweeteners may comprise but not limited to aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose or sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof. Suitable flavoring agents may comprise but not limited to menthol, peppermint, cinnamon, chocolate, vanillin or fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries or mixtures thereof.
Suitable coloring agents may comprise but not limited to ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof. Example 1 :
Figure imgf000011_0001
Production process of Dronedarone HCI pellets: Dronedarone HCI, mannitol and pregelatinized starch are mixed together then by spraying polyvinyl pyrrolidone solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding cellulose acetate phthalate as enteric coating and the dronedarone HCI are coated by spraying this mixture.
Production processes of Organic acid pellets are coated with Dabigatran: Adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum are mixed together. Alcoholic polyvinyl alcohol (PVA) or I PA (isopropyl alcohol) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique. The pellets are coated with sodium alginate in fluidized bed so acid pellets are manufactured. DEM (dabigatran etaxylate mesylate) is dissolved in alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution. This solution is sprayed onto the acid pellet by fluidized bed pelletizing technique so multilayer pellets are manufactured.
The DEM and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules.
Example 2: ingredients amount (%)
Dronedarone HCI pellets
dronedarone HCI 5.00 - 98.00
mannitol 5.00 - 90.00
pregelatinized starch 5.00 - 90.00
carbomer 0.10 - 30.00
Enteric coating
copolymer of ethyl acrylate, 0.10 - 30.00
methyl methacrylate and
ammonia methacrylate
Dabigatran etexilate
mesylate pellets
dabigatran etexilate 1.00 - 85.00
mesylate
adipic acid or sorbic acid or 5.00 - 95.00
succinic acid or glutaric acid
methacrylic acid-Ethyl 0.05 - 40.00
acrylate copolymer (Eudragit
EPO) or PVA
mannitol 5.0 - 90.00
xanthan gum 0.05 - 5.00 magnesium stearate 0.10 - 3.00
silicon dioxide 0.10 - 1.00 Production process of Dronedarone HCI pellets: Dronedarone HCI, mannitol and pregelatinized starch are mixed together then by spraying carbomer solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding copolymer of ethyl acrylate, methyl methacrylate and ammonia methacrylate as enteric coating and the dronedarone HCI pellets are coated by spraying this mixture in fluidized bed.
Production process of Dabigatran pellets: DEM and mannitol are mixed together. Alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique. The solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum. This solution is sprayed onto the DEM pellets by fluidized bed pelletizing technique so multilayer pellets are manufactured. The DEM and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules.
Example 3: ingredients amount (%)
Dronedarone HCI pellets
dronedarone HCI 5.00 - 98.00
mannitol 5.00 - 90.00
croscarmellose sodium 5.00 - 40.00
carbomer 0.10 - 30.00
Enteric coating
methacrylic acid, methyl 0.10 - 30.00
methacrylate copolymer
Dabigatran etexilate
mesylate pellets
dabigatran etexilate 1.00 - 85.00
mesylate
sugar pellet 5.00 - 90.00
polyvinylpyrrolidone (PVP) 0.10 - 30.00
methacrylic acid-ethyl 0.05 - 40.00
acrylate copolymer (Eudragit EPO) or PVA
Inorganic acid pellets
nitric acid 0.05 - 10.00
microcrystalline cellulose or 5.0 - 40.00
mannitol or lactose
silicon dioxide 0.1 - 0.20
methacrylic acid-ethyl 0.05 - 40.00
acrylate copolymer (Eudragit
EPO) or PVA silicon dioxide 0.10 - 1.00
magnesium stearate 0.10 - 3.00
Production process of Dronedarone HCI pellets: Dronedarone HCI, mannitol and croscarmellose sodium are mixed together then by spraying carbomer solution a wet mass is formed. Pellets produced from this wet mass by extrusion/spheronization pelletizing technique. A solution/dispersion is prepared by adding methacrylic acid, methyl methacrylate copolymer as enteric coating and the dronedarone HCI pellets which were coated with the enteric coating by spraying this mixture.
Production process of Dabigatran pellets: Alcoholic solution/dispersion is prepared by adding DEM and PVP. Sugar pellets are coated with this solution/dispersion. The sugar pellets which were coated with the active ingredient are coated with methacrylic acid-ethyl acrylate copolymer (Eudragit EPO or Polyvinyl alcohol (PVA) and then with PVP solution so DEM pellets are manufactured. Production Process of inorganic acid pellets: Microcrystalline cellulose or mannitol or lactose and silicon dioxide are blended, then by spraying dilute nitric acid soution a wet mass is formed by high shear granulator or fluid bed granulator. The pellets are coated by methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution in fluidized bed so inorganic acid pellets are manufactured.
Dronedarone pellets and Dabigatran etexilate mesylate pellets and inorganic acid pellets are mixed. The pellets are first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed as tablets or filled into the capsules. Example 4:
Figure imgf000015_0001
Production process multilayer pellets: A solution/dispersion is prepared by adding dronedarone and PVP. Sugar pellets are coated with this solution/dispersion. The sugar pellets which were coated with the dronedarone HCI are coated with polyvinyl acetate phthalate so dronedarone HCI pellets are manufactured. DEM and mannitol are mixed with alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution. This mixture is sprayed onto dronedarone HCI pellets. The solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid) and xanthan gum. This solution is sprayed onto the pellets so multilayer pellets are manufactured. Finally the multilayer pellets are coated by PVA. The multilayer pellets first mixed with silicon dioxide and then with magnesium stearate. The pellets are pressed as tablets or filled into the capsules. Example 5:
Figure imgf000016_0001
Production process of Dronedarone HCI pellets: A solution/dispersion is prepared by adding Dronedarone HCI and PVP. Sugar pellets are coated with this solution/dispersion. The sugar pellets which were coated with the active ingredient are coated with methacrylic acid co-polymer type C so Dronedarone HCI pellets are manufactured.
Production process of Dabigatran pellets are coated with organic acid: DEM and mannitol monohydrate are mixed together. Alcoholic methacrylic acid-ethyl acrylate copolymer (Eudragit EPO) or polyvinyl alcohol (PVA) solution is sprayed onto this mixture and pellets produced by fluidized bed pelletizing technique.The solution is prepared by adding adipic acid or sorbic acid or succinic acid or glutaric acid and xanthan gum. This solution is sprayed onto the DEM pellets by fluidized bed pelletizing technique so multilayer pellets are manufactured.
Dabigatran etexilate mesylate and dronedarone HCI pellets first mixed with silicon dioxide and then with magnesium stearate. Finally, the pellets are pressed by multilayer rotary tablet press machine or dry tablet in tablet or inlay tablets which have dronedarone HCI pellets on the core are produced with special tablet press machine.

Claims

1. A pharmaceutical combination comprising dronedarone or a pharmaceutically acceptable salt in combination with dabigatran or a pharmaceutically acceptable salt or polymorph thereof and at least one pharmaceutically acceptable excipient.
2. The pharmaceutical combination according to claim 1 , wherein dronedarone or a pharmaceutically acceptable salt is dronedarone hydrochloride.
3. The pharmaceutical combination according to claim 1 or 2, wherein dronedarone hydrochloride is present in an amount of between 5.0 to 98.0 %, preferably between 20.0 to 98.0 % and more preferably it is 50.0 to 95.0 % by weight of total formulation.
4. The pharmaceutical combination according to claim 3, wherein dronedarone hydrochloride present in an amount of between 50 to 1000 mg, preferably 200 to 800 mg and more preferably it is 400 to 800 mg.
5. The pharmaceutical combination according to claim 1 , wherein dabigatran or a pharmaceutically acceptable salt or polymorph is etexilate or etexilate mesylate salt of dabigatran.
6. The pharmaceutical combination according to claim 5, dabigatran or a pharmaceutically acceptable salt is dabigatran etexilate mesylate.
7. The pharmaceutical combination according to claim 1 , wherein dabigatran etexilate mesylate is present in an amount of between 1.0 to 85.0 %, preferably between 1 .0 to 60.0 % and more preferably it is 5.0 to 50.0 % by weight of total formulation.
8. The pharmaceutical combination according to claim 7, wherein dabigatran etexilate mesylate is present in an amount of between 30 to 350 mg, preferably 50 to 300 mg and more preferably it is 50 to 250 mg.
9. The pharmaceutical combination according to claim 1 , wherein the ratio of dronedarone HCI to dabigatran etexilate mesylate which is between 0.10 - 50.0 (w/w), preferably 1.0 - 35.0 (w/w) and more preferably 1.0 - 30.0 (w/w).
10. The pharmaceutical combination according to claim 1 , wherein said pharmaceutical combination is in the form of solid, liquid or semisolid dosage form.
1 1 . The pharmaceutical combination according to claim 10, wherein said pharmaceutical combination is formulated as tablets, coated or uncoated tablets, capsules, multilayer tablets, buccal tablets, sublingual tablets, tablet in tablets, in-lay tablets, effervescent combinations, effervescent tablets, immediate release tablets, modified release tablets, orally disintegrating tablet, film-coated tablets, orally disintegrating tablets, gastric disintegrating tablets, pills, hard or soft gelatin capsules, powders, mini tablets, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, sterile solutions or suspensions, sterile ocular solutions, aerosols, sprays, drops, ampoules, suppositories, ocular systems, parenteral systems, creams, gels, ointments, dragees, sachets; films, orally administrable films, solutions, solids; elixirs, tinctures, suspensions, syrups, colloidal dispersions, dispersions, emulsions.
12. The pharmaceutical combination according to claim 1 1 , wherein said pharmaceutical combination is formulated in the form of tablet or capsule or multilayer tablet.
13. The pharmaceutical combination according to claim 12, wherein said pharmaceutical combination is formulated in the form of tablet or capsule or multilayer tablet comprising dabigatran etexilate mesylate pellets and dronedarone HCI pellets.
14. The pharmaceutical combination according to claim 13, wherein said dronedarone HCI pellets comprising an enteric coating.
15. The pharmaceutical combination according to claim 14, wherein the enteric coating is selected from the group comprising cellulose acetate phthalate, methacrylic acid copolymers, methacrylic acid, ethyl acrylate copolymers, copolymer of ethyl acrylate, methyl methacrylate and ammonia methacrylate; methacrylic acid, methyl methacrylate copolymer, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate and methacrylic acid co-polymer type C.
16. The pharmaceutical combination according to claim 13, wherein said pharmaceutical combination is in the form of tablet or capsule or multilayer tablet comprising dronedarone HCI pellets and dabigatran etexilate mesylate pellets which are in the form of separate pellets or bilayer pellets or multilayer pellets.
17. The pharmaceutical combination according to claim 1 , wherein at least one pharmaceutically acceptable excipient is selected from the group comprising buffering agents, stabilizers, binders, diluents, dispersing agents, lubricants, glidants, disintegrants, plasticizers, preservatives, sweeteners, flavoring agents, coloring agents, acids or mixtures thereof.
The pharmaceutical combination according to claim 16, wherein said dronedarone HCI pellets comprising mannitol or pregelatinized starch or carbomer or croscarmellose sodium or polyvinylpyrrolidone or polyvinyl alcohol or sugar pellet or microcrystalline cellulose pellet or hydroxypropyl cellulose or coloring agent or mixtures thereof as pharmaceutically acceptable excipients.
19. The pharmaceutical combination according to claim 16, wherein said dabigatran etexilate mesylate pellets comprising polyvinyl alcohol or isopropyl alcohol or sodium alginate or methacrylic acid-ethyl acrylate copolymer or propylene glycol or lactose monohydrate or mannitol or sugar pellet or polyvinylpyrrolidone or mixtures thereof
20. The pharmaceutical combination according to claim 1 , for use in the treatment of cardiac arrhythmia and blood clotting and to prevent serious or life- threatening side effects in patients.
PCT/EP2016/053819 2015-02-25 2016-02-24 Pharmaceutical combinations of dronedarone and dabigatran Ceased WO2016135171A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2015/02223 2015-02-25
TR2015/02223A TR201502223A2 (en) 2015-02-25 2015-02-25 Pharmaceutical combinations of dronedarone and dabigatran

Publications (1)

Publication Number Publication Date
WO2016135171A1 true WO2016135171A1 (en) 2016-09-01

Family

ID=53502822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/053819 Ceased WO2016135171A1 (en) 2015-02-25 2016-02-24 Pharmaceutical combinations of dronedarone and dabigatran

Country Status (2)

Country Link
TR (1) TR201502223A2 (en)
WO (1) WO2016135171A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471609B1 (en) 1990-08-06 1996-11-27 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
WO1998037075A1 (en) 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
EP1870100A1 (en) 2002-03-07 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition for oral application comprising ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate mesylate
US7323493B1 (en) 1997-06-23 2008-01-29 Sanofi-Aventis Solid pharmaceutical composition containing benzofuran derivatives
US20110136779A1 (en) * 2009-11-23 2011-06-09 Milner Peter G Methods for stroke reduction in atrial fibrillation patients
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471609B1 (en) 1990-08-06 1996-11-27 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
WO1998037075A1 (en) 1997-02-18 1998-08-27 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, their production and use as medicaments
US7323493B1 (en) 1997-06-23 2008-01-29 Sanofi-Aventis Solid pharmaceutical composition containing benzofuran derivatives
EP1870100A1 (en) 2002-03-07 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition for oral application comprising ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate mesylate
US20110136779A1 (en) * 2009-11-23 2011-06-09 Milner Peter G Methods for stroke reduction in atrial fibrillation patients
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. G VISHWAKARMA ET AL: "Bi-Layer Tablet -A New Ways in Oral Drug Delivery System", INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH CODEN (USA), vol. 6, no. 5, October 2014 (2014-10-01), pages 1416 - 1428, XP055206478 *

Also Published As

Publication number Publication date
TR201502223A2 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
EP1096937B9 (en) Sustained release ranolazine formulations
CA2402222C (en) Sustained release ranolazine formulations
MX2007007836A (en) Method for stabilizing anti-dementia drug.
EP2929884A1 (en) Pharmaceutical combinations of dabigatran and h2-receptor antagonists
JP7571394B2 (en) Orally disintegrating tablets containing edoxaban
WO2015155281A1 (en) Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN103648485A (en) Pharmaceutical composition of rosuvastatin calcium
US20100136119A1 (en) Controlled-release preparation containing cilostazol and process for the preparation thereof
WO2015169957A1 (en) Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists
RS58263B1 (en) Vortioxetine pyroglutamate
CA2606740A1 (en) Quinine-containing controlled-release formulations
WO2015155307A1 (en) Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
WO2014060545A1 (en) Pharmaceutical compositions of dabigatran free base
EP3103444A1 (en) Pharmaceutical compositions of lacosamide and eslicarbazepine
PT2533766E (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
EP2722037A1 (en) Prasugrel formulations
WO2016131896A1 (en) Pharmaceutical combinations of dronedarone and rivaroxaban
WO2016135171A1 (en) Pharmaceutical combinations of dronedarone and dabigatran
EP3342401A1 (en) Bilayer tablet formulations of dabigatran etexilate
EP3324946A1 (en) Pharmaceutical formulations of dabigatran free base
WO2019203748A2 (en) The composition comprising raloxifene with at least one antipsychotic agent
WO2017134200A1 (en) A novel pharmaceutical composition of vorapaxar and metoprolol
EP3246020A1 (en) New oral pharmaceutical formulations of dabigatran
WO2014027974A1 (en) Orally disintegrating formulation of paliperidone
WO2017134199A1 (en) A pharmaceutical composition of vorapaxar and metoprolol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16707685

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16707685

Country of ref document: EP

Kind code of ref document: A1